Lopinavir + Ritonavir 200/50mgTablet
HIV / Antiretroviral

Lopinavir + Ritonavir 200/50mg

Lopinavir + Ritonavir

Fixed-dose combination where sub-therapeutic ritonavir inhibits CYP3A4 to dramatically boost lopinavir plasma levels, achieving reliable viral suppression without food restrictions for the tablet formulation. Widely used in pediatric HIV as oral solution and an affordable PEPFAR-supported generic in resource-limited settings globally.

Strengths

200mg + 50mg (tablet); 80mg + 20mg/mL (solution)

Packing

30 tablets/bottle

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Request QuotationWhatsApp
Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition
Lopinavir 200mg + Ritonavir 50mg per tablet
Dosage Form
Tablet
Available Strengths
200mg + 50mg (tablet); 80mg + 20mg/mL (solution)
Packing
30 tablets/bottle
Route of Administration
Oral, with food (film-coated tablets can be taken with or without food)
Dosage
Treatment-naive: 800/200mg once daily or 400/100mg twice daily; Treatment-experienced: 400/100mg twice daily (once daily not recommended)
Indications
HIV-1 infection in adults and pediatric patients, in combination with other antiretrovirals
Country of Origin
India (WHO-GMP Certified)
Storage
Store at 25°C (tablets); refrigerate solution at 2-8°C or store at ≤25°C for up to 2 months
Shelf Life
36 months
Side Effects
Diarrhea, nausea, vomiting, dyslipidemia, hyperglycemia, QT and PR prolongation, hepatotoxicity, fat redistribution
Precautions
Extensive CYP3A4 drug interactions (ritonavir is a strong inhibitor); lipid monitoring; QTc prolongation monitoring; hepatotoxicity in viral hepatitis coinfection; pancreatitis risk

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Efavirenz 600mgTablet

Efavirenz 600mg

Efavirenz

Second-generation NNRTI that allosterically inhibits HIV-1 reverse transcriptase, a backbone of PEPFAR-supported first-line HIV treatment in sub-Saharan Africa and Southeast Asia. Available in the landmark fixed-dose combination TDF/3TC/EFV (Atripla/generic), which transformed HIV care globally with a once-daily single-pill regimen.

50mg / 200mg / 600mg
Atazanavir + Ritonavir 300/100mgCapsule

Atazanavir + Ritonavir 300/100mg

Atazanavir + Ritonavir

Ritonavir-boosted azapeptide protease inhibitor distinguished by its unique pharmacokinetic characteristic of causing benign indirect hyperbilirubinemia (marker of absorption), once-daily dosing convenience, and a significantly more favorable lipid profile than lopinavir/ritonavir. Preferred second-line choice in resource-limited settings and in patients with dyslipidemia or cardiovascular risk.

150mg / 200mg / 300mg (atazanavir); 100mg (ritonavir)
Abacavir + Lamivudine 600/300mgTablet

Abacavir + Lamivudine 600/300mg

Abacavir + Lamivudine

Dual NRTI backbone combining abacavir and lamivudine in a once-daily tablet forming the nucleoside backbone of multiple WHO-recommended HIV regimens. Mandatory HLA-B*5701 pharmacogenomic screening before use is required to prevent the potentially fatal abacavir hypersensitivity syndrome — a landmark example of precision medicine applied in HIV therapy.

600mg + 300mg

Need bulk pricing for Lopinavir + Ritonavir 200/50mg?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote